MicroRNA-122-5p inhibits cell proliferation, migration and invasion by targeting CCNG1 in pancreatic ductal adenocarcinoma.

作者: Chen Dai , Yan Zhang , Zhihua Xu , Mengxian Jin

DOI: 10.1186/S12935-020-01185-Z

关键词:

摘要: Pancreatic ductal adenocarcinoma (PDAC) is a lethal human malignancy, and previous researches support the contribution of microRNA (miRNA) to cancer progression. MiR-122-5p reported participate in regulation various cancers, while function miR-122-5p PDAC remains unclear. In this study, we investigated precise mechanism involved pathogenesis. The expression levels were detected tissues cell lines by miRNA RT-PCR. effects on proliferation explored MTT assays, colony formation assays flow cytometry assays. ability migration invasion was determined transwell Dual Luciferase reporter assay performed validate direct interaction between its target gene. related molecules cycle, apoptosis epithelial–mesenchymal transition (EMT) examined with qRT-PCR western blot. addition, xenograft mouse models applied explore vivo. underexpressed, CCNG1 highly expressed cells. negatively correlated TNM stage, tumor size lymph node metastasis patients. Overexpression suppressed proliferation, vitro inhibited tumorigenesis Furthermore, miR-122-5p. Upregulated could partially reverse caused Moreover, EMT through downregulation CCNG1. inhibit migration, invasion, downregulating PDAC, suggesting potential therapeutic for PDAC.

参考文章(39)
S. Vynckier, R. Schmidt, The Physical Basis for Radiotherapy with Neutrons Recent results in cancer research. ,vol. 150, pp. 1- 30 ,(1998) , 10.1007/978-3-642-78774-4_1
Sercan Ergün, Mustafa Ulasli, Yusuf Ziya Igci, Mehri Igci, Sevil Kırkbes, Ersin Borazan, Ahmet Balik, Önder Yumrutaş, Celalettin Camci, Ecir Ali Cakmak, Ahmet Arslan, Serdar Oztuzcu, The association of the expression of miR-122-5p and its target ADAM10 with human breast cancer Molecular Biology Reports. ,vol. 42, pp. 497- 505 ,(2015) , 10.1007/S11033-014-3793-2
Xing-Xing Ye, Chi-Bo Liu, Jia-yu Chen, Bao-hong Tao, Cai Zhi-yi, The expression of cyclin G in nasopharyngeal carcinoma and its significance Clinical and Experimental Medicine. ,vol. 12, pp. 21- 24 ,(2012) , 10.1007/S10238-011-0142-9
Mary C. Horne, Gay Lynn Goolsby, Karen L. Donaldson, David Tran, Michael Neubauer, Alan F. Wahl, Cyclin G1 and cyclin G2 comprise a new family of cyclins with contrasting tissue-specific and cell cycle-regulated expression. Journal of Biological Chemistry. ,vol. 271, pp. 6050- 6061 ,(1996) , 10.1074/JBC.271.11.6050
Jing Yan, Jing-yi Jiang, Xiao-Na Meng, Yin-Ling Xiu, Zhi-Hong Zong, MiR-23b targets cyclin G1 and suppresses ovarian cancer tumorigenesis and progression Journal of Experimental & Clinical Cancer Research. ,vol. 35, pp. 31- 31 ,(2016) , 10.1186/S13046-016-0307-1
Dan Calatayud, Christian Dehlendorff, Mogens K. Boisen, Jane Preuss Hasselby, Nicolai Aagaard Schultz, Jens Werner, Heike Immervoll, Anders Molven, Carsten Palnæs Hansen, Julia S. Johansen, Tissue MicroRNA profiles as diagnostic and prognostic biomarkers in patients with resectable pancreatic ductal adenocarcinoma and periampullary cancers Biomarker research. ,vol. 5, pp. 8- 8 ,(2017) , 10.1186/S40364-017-0087-6
ReenaRachel John, N Malathi, C Ravindran, Soumya Anandan, Mini review: Multifaceted role played by cyclin D1 in tumor behavior. Indian Journal of Dental Research. ,vol. 28, pp. 187- 192 ,(2017) , 10.4103/IJDR.IJDR_697_16
Ji Ma, Tengfei Li, Xinwei Han, Huifeng Yuan, Knockdown of LncRNA ANRIL suppresses cell proliferation, metastasis, and invasion via regulating miR-122-5p expression in hepatocellular carcinoma Journal of Cancer Research and Clinical Oncology. ,vol. 144, pp. 205- 214 ,(2018) , 10.1007/S00432-017-2543-Y
Thomas Brabletz, Raghu Kalluri, M. Angela Nieto, Robert A. Weinberg, EMT in cancer Nature Reviews Cancer. ,vol. 18, pp. 128- 134 ,(2018) , 10.1038/NRC.2017.118
Frauke G. Heinemann, Yuri Tolkach, Mario Deng, Doris Schmidt, Sven Perner, Glen Kristiansen, Stefan C. Müller, Jörg Ellinger, Serum miR-122-5p and miR-206 expression: non-invasive prognostic biomarkers for renal cell carcinoma Clinical Epigenetics. ,vol. 10, pp. 11- ,(2018) , 10.1186/S13148-018-0444-9